- CRTX is pursuing a highly speculative hypothesis that gingivitis plays a role in the pathogenesis of Alzheimer's Disease (AD).
- Top line results for AD Phase 2/3 trial expected mid-November; success would be one of the greatest medical breakthroughs in modern history.
- Success in a sub-study treatment of gingivitis should provide downside cushion if AD fails.
- Options strategies are discussed as a way to minimize investment risk and take advantage of both high optimism and pessimism from option traders.
For further details see:
Cortexyme: Alzheimer's Readout In November A Binary Event